Online Database of Chemicals from Around the World

(2S,4R)-N-[2-氯-1-[(2R,3S,4S,5R,6R)-3,4,5-三羟基-6-甲硫基-四氢吡喃-2-基]丙基]-1-甲基-4-丙基-吡咯烷-2-甲酰胺
[CAS# 24696-19-3]

供应商
Achemica 瑞士 询价快递  
+41 (24) 466-2929
contact@achemica.com
化学品生产商(2010 年起)
Interbioscreen Ltd. 俄罗斯 询价快递  
+7 (49) 6524-0091
screen@ibscreen.chg.ru
化学品生产商
RIA International LLC 美国 询价快递  
+1 (973) 581-1282/
marketing@riausa.net,nj@riausa.net
化学品供销商
TimTec 美国 询价快递  
+1 (302) 292-8500
info@timtec.com
化学品生产商
基本信息
产品名称 (2S,4R)-N-[2-氯-1-[(2R,3S,4S,5R,6R)-3,4,5-三羟基-6-甲硫基-四氢吡喃-2-基]丙基]-1-甲基-4-丙基-吡咯烷-2-甲酰胺
英文名 (2S,4R)-N-[2-Chloro-1-[(2R,3S,4S,5R,6R)-3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide
别名 (2S,4R)-N-[2-Chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-Methylsulfanyl-Tetrahydropyran-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide; (2S,4R)-N-[2-Chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-(Methylthio)-2-Tetrahydropyranyl]Propyl]-1-Methyl-4-Propyl-2-Pyrrolidinecarboxamide; (2S,4R)-N-[2-Chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-(Methylthio)Tetrahydropyran-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide
分子结构 CAS 登录号:24696-19-3, (2S,4R)-N-[2-氯-1-[(2R,3S,4S,5R,6R)-3,4,5-三羟基-6-甲硫基-四氢吡喃-2-基]丙基]-1-甲基-4-丙基-吡咯烷-2-甲酰胺
分子式 C18H33ClN2O5S
分子量 424.98
CAS 登录号 24696-19-3
分子行输入简码 SMILES [C@@H]1(N(C[C@@H](C1)CCC)C)C(=O)NC([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)C(Cl)C
国际化学标识码 InChI 1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1
国际化学标识检索码 InChIKey KDLRVYVGXIQJDK-NOWPCOIGSA-N
物理化学性质
密度 1.299g/cm3 (计算值)
沸点 628.077°C at 760 mmHg (计算值)
闪点 333.649°C (计算值)
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Clearance , "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Clearance' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in (ml/min/kg) units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Clearance' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (10+-4), Clavulanate (3.6+-1.0), Enoxaparin (0.3+-0.1), Epoetin Alfa (0.047+-0.017 (0.047-0.092)), Etanercept (0.02), Filgrastim (0.5-0.7), Heparin (1/(0.65 + 0/0.008D) +- 0.1), Interferon Alfa (2.8+-0.6), Interferon Beta (13+-5), Lithium (0.35+-0.11), Mycophenolate (MM: 120-163, MPA: 2.5+-0.4), Prednisolone (1.0+-0.16), Rapacuronium (7-11), Sargramostim (A: 420 ml/min/(m.m), C:49(15-118) ml/min/(m.m)) and Streptokinase (1.7+-0.7) have not been provided here. In all, 301 drugs and their 'Clearance' values are given in the files here.
市场分析报告
请浏览(2S,4R)-N-[2-氯-1-[(2R,3S,4S,5R,6R)-3,4,5-三羟基-6-甲硫基-四氢吡喃-2-基]丙基]-1-甲基-4-丙基-吡咯烷-2-甲酰胺市场分析报告总目录
相关产品
1,1'-[(6-苯氧基-s-三嗪-2,4-二基)...  7,7,9-三甲基-1-氧杂-4-硫杂螺[4.5]...  3-[(4-叔-丁基环己基)氧基]-1-丙硫醇  对甲苯基 3-甲基巴豆酸酯  3,4-二氢-4-异丙基-2,2-二甲基-7-辛基...  S-苄基-S-苯基-N-对甲苯磺酰硫亚胺  1,10-二(1,3-二苯基-5-氧代-2-吡唑啉...  4,4'-联苯亚基二(三甲基铵)二(硫酸甲酯盐)  6-羟基倍他米松  雌二醇-3-葡糖苷  (+)-双环大根香叶烯  原夏至草苦素  二庚基胺  2-[2-[4-(2-甲基-3-吩噻嗪-10-基丙...  2-(2-甲基-咪唑-1-羰基)-苯甲酸